Cargando…

Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease

In patients with nonalcoholic fatty liver disease (NAFLD), prognosis and outcome, especially non‐liver‐related mortality, remain incompletely elucidated. We clarified the mortality from all causes in patients with NAFLD. A total of 4,073 patients with NAFLD diagnosed by ultrasonography were enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Tada, Toshifumi, Kumada, Takashi, Toyoda, Hidenori, Mizuno, Kazuyuki, Sone, Yasuhiro, Akita, Tomoyuki, Tanaka, Junko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721461/
https://www.ncbi.nlm.nih.gov/pubmed/29404500
http://dx.doi.org/10.1002/hep4.1105
_version_ 1783284811042914304
author Tada, Toshifumi
Kumada, Takashi
Toyoda, Hidenori
Mizuno, Kazuyuki
Sone, Yasuhiro
Akita, Tomoyuki
Tanaka, Junko
author_facet Tada, Toshifumi
Kumada, Takashi
Toyoda, Hidenori
Mizuno, Kazuyuki
Sone, Yasuhiro
Akita, Tomoyuki
Tanaka, Junko
author_sort Tada, Toshifumi
collection PubMed
description In patients with nonalcoholic fatty liver disease (NAFLD), prognosis and outcome, especially non‐liver‐related mortality, remain incompletely elucidated. We clarified the mortality from all causes in patients with NAFLD. A total of 4,073 patients with NAFLD diagnosed by ultrasonography were enrolled. We investigated the causes of death and analyzed the mortality from non‐liver‐related diseases according to the degrees of steatosis and fibrosis using the competing risk method. We used the NAFLD fibrosis score (NFS) to assess fibrosis severity and the ultrasonography fatty liver score to evaluate steatosis severity. The numbers of patients with NFS indicating low, intermediate, and high probabilities of advanced fibrosis were 2,451 (60.2%), 1,462 (35.9%), and 160 (3.9%), respectively. Of the 4,073 patients, 179 died during follow‐up, but only nine deaths were due to liver‐related diseases. Of the remaining 170 patients who died due to non‐liver‐related diseases, 83 (48.8%), 42 (24.7%), and 45 (26.5%) patients died due to malignancies, cerebrovascular and cardiovascular diseases, and benign diseases (excluding cerebrovascular and cardiovascular diseases), respectively. Multivariate analysis showed that the intermediate and high NFS groups were independently associated with each disease category: hazard ratio (HR) 2.163 (95% confidence interval [CI], 1.354‐3.457) and HR 4.814 (95% CI, 2.323‐9.977) for malignancies; HR 2.265 (95% CI, 1.141‐4.497) and HR 8.482 (95% CI, 3.558‐20.220) for cerebrovascular and cardiovascular diseases; and HR 3.216 (95% CI, 1.641‐6.303) and HR 5.558 (95% CI, 1.923‐16.070) for benign diseases, respectively. Conversely, the status of steatosis was not associated with risk of mortality in multivariate analysis. Conclusion: Progression of liver fibrosis severity was associated with mortality from various non‐liver‐related causes in patients with NAFLD. (Hepatology Communications 2017;1:928–945)
format Online
Article
Text
id pubmed-5721461
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57214612018-02-05 Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease Tada, Toshifumi Kumada, Takashi Toyoda, Hidenori Mizuno, Kazuyuki Sone, Yasuhiro Akita, Tomoyuki Tanaka, Junko Hepatol Commun Original Articles In patients with nonalcoholic fatty liver disease (NAFLD), prognosis and outcome, especially non‐liver‐related mortality, remain incompletely elucidated. We clarified the mortality from all causes in patients with NAFLD. A total of 4,073 patients with NAFLD diagnosed by ultrasonography were enrolled. We investigated the causes of death and analyzed the mortality from non‐liver‐related diseases according to the degrees of steatosis and fibrosis using the competing risk method. We used the NAFLD fibrosis score (NFS) to assess fibrosis severity and the ultrasonography fatty liver score to evaluate steatosis severity. The numbers of patients with NFS indicating low, intermediate, and high probabilities of advanced fibrosis were 2,451 (60.2%), 1,462 (35.9%), and 160 (3.9%), respectively. Of the 4,073 patients, 179 died during follow‐up, but only nine deaths were due to liver‐related diseases. Of the remaining 170 patients who died due to non‐liver‐related diseases, 83 (48.8%), 42 (24.7%), and 45 (26.5%) patients died due to malignancies, cerebrovascular and cardiovascular diseases, and benign diseases (excluding cerebrovascular and cardiovascular diseases), respectively. Multivariate analysis showed that the intermediate and high NFS groups were independently associated with each disease category: hazard ratio (HR) 2.163 (95% confidence interval [CI], 1.354‐3.457) and HR 4.814 (95% CI, 2.323‐9.977) for malignancies; HR 2.265 (95% CI, 1.141‐4.497) and HR 8.482 (95% CI, 3.558‐20.220) for cerebrovascular and cardiovascular diseases; and HR 3.216 (95% CI, 1.641‐6.303) and HR 5.558 (95% CI, 1.923‐16.070) for benign diseases, respectively. Conversely, the status of steatosis was not associated with risk of mortality in multivariate analysis. Conclusion: Progression of liver fibrosis severity was associated with mortality from various non‐liver‐related causes in patients with NAFLD. (Hepatology Communications 2017;1:928–945) John Wiley and Sons Inc. 2017-09-26 /pmc/articles/PMC5721461/ /pubmed/29404500 http://dx.doi.org/10.1002/hep4.1105 Text en © 2017 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Tada, Toshifumi
Kumada, Takashi
Toyoda, Hidenori
Mizuno, Kazuyuki
Sone, Yasuhiro
Akita, Tomoyuki
Tanaka, Junko
Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
title Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
title_full Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
title_fullStr Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
title_full_unstemmed Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
title_short Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
title_sort progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721461/
https://www.ncbi.nlm.nih.gov/pubmed/29404500
http://dx.doi.org/10.1002/hep4.1105
work_keys_str_mv AT tadatoshifumi progressionofliverfibrosisisassociatedwithnonliverrelatedmortalityinpatientswithnonalcoholicfattyliverdisease
AT kumadatakashi progressionofliverfibrosisisassociatedwithnonliverrelatedmortalityinpatientswithnonalcoholicfattyliverdisease
AT toyodahidenori progressionofliverfibrosisisassociatedwithnonliverrelatedmortalityinpatientswithnonalcoholicfattyliverdisease
AT mizunokazuyuki progressionofliverfibrosisisassociatedwithnonliverrelatedmortalityinpatientswithnonalcoholicfattyliverdisease
AT soneyasuhiro progressionofliverfibrosisisassociatedwithnonliverrelatedmortalityinpatientswithnonalcoholicfattyliverdisease
AT akitatomoyuki progressionofliverfibrosisisassociatedwithnonliverrelatedmortalityinpatientswithnonalcoholicfattyliverdisease
AT tanakajunko progressionofliverfibrosisisassociatedwithnonliverrelatedmortalityinpatientswithnonalcoholicfattyliverdisease